IPO Premiums
IPO calendar
GPListed

Goldline Pharmaceutical Limited

Bookbuilding IPO · BSE

Price band
₹41 - ₹43
Lot size
3,000 shares
Issue amount
₹11.61 cr
Total subscription
840.81×
Current price₹32
Listing price ₹59.75
Watch live price ↗
Opens
12 May 2026
Closes
14 May 2026
Allotment
15 May 2026
Listing
19 May 2026

Offer at a glance

Issue overview

Issue size
27,00,000 shares
Face value
₹10 per share
Minimum investment
₹1,23,000
Fresh issue
₹11.61 cr
Offer for sale
₹0 cr
Registrar
Bigshare Services Private Limited
Listing exchange
BSE
Maximum investment
₹1,29,000
Issue type
Bookbuilding IPO
Shares before issue
69,00,000
Shares after issue
96,00,000

Lot sizes

CategoryLotsSharesAmount
RETAIL26,000₹2,58,000
sHNI39,000₹3,87,000
bHNI824,000₹10,32,000

Share reservation

Anchor27.11%
QIB20%
HNI14.44%
RETAIL33.33%
Market Maker5.11%

Subscription & GMP

Subscription by category

Total subscribed840.81×

Reported 14 May 2026

QIB180.22×
NIB1,662.39×
RETAIL881.15×
HNIs(10L+)1,995.67×
HNIs(2-10L)995.84×

GMP history

07.51514 May: ₹1215 May: ₹1519 May: ₹12
14 May₹1219 May

Day-wise demand

12 May22.35×
13 May100.21×
14 May840.81×

Application-wise demand

CategoryReserved applicationsApplied applications
QIB085
NIB033,760
RETAIL1501,32,173
EMPLOYEES00
HNIs(10L +)2920,429
HNIs (2-10L)1413,331
Shareholder00

Subscription demand

Amounts in ₹ crore. HNI subcategories are included in the NII total.

CategoryOfferedDemand
QIBs2.32418.46
FIIs0109.38
Others0309.05
RETAIL3.873,410.06
HNIs 2+0.56556.67
HNIs 10+1.122,231.16

Financial performance

Company financials

In Crores · Reported periods may include interim results.

Revenue & profitIn Crores
0102030Mar-23 · Revenue: 19.85Mar-23 · Profit after tax: 0.26Mar-23Mar-24 · Revenue: 23.57Mar-24 · Profit after tax: 1.81Mar-24Mar-25 · Revenue: 28.06Mar-25 · Profit after tax: 2.83Mar-25Dec-25 · Revenue: 21.4Dec-25 · Profit after tax: 2.22Dec-25
RevenueProfit after tax

Key performance indicators

MetricDec-25Mar-25Mar-24
EPS3.224.13.01
ROE21.0235.8331.31
ROCE000
RONW000
PRE IPO(PE)010.470
POST IPO(PE)14.5600

Values and labels as reported in the issue data.

Peer comparison

CompanyP/E(X)CMP* (₹)Face value (₹)NAV/Share (₹)RONW(%)EPS (Basic) (₹)
Goldline Pharmaceutical Limited10.4701012.3827.374.1
Mono Pharmacare Limited7.5701017.669.91.75
Chandra Bhagat Pharma Limited28.9401039.722.861.14

Company information

Company profile

Goldline Pharmaceuticals markets pharmaceutical products under the “Goldline” brand, offering a wide range of medicines across five divisions—Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. These products cater to various medical specialties including physicians, cardiologists, pediatricians, orthopedics, neurologists, critical care experts, and cancer supportive care. Instead of manufacturing medicines directly, the company works with third-party manufacturers who produce products based on its research and specifications while ensuring quality and regulatory compliance. Goldline sells its products through a network of distributors, retailers, and wholesalers, and also supports hospitals and healthcare providers with procurement and supply services. The company currently partners with 15 manufacturers and 7 distributors, with operations spread across states like Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.

Strengths

  • Asset-Light & Scalable Business Model: Outsourced manufacturing approach reduces capital requirements and supports expansion.
  • Diversified Pharmaceutical Portfolio: Wide range of products across multiple therapeutic segments reduces dependency on one category.
  • Strong Distribution & Supplier Network: Established relationships with manufacturers and distributors ensure smooth operations.

Risk factors

  • Dependence on Third-Party Manufacturers: Reliance on external manufacturers may impact quality control and supply continuity.
  • Regulatory Compliance Risks: Pharmaceutical industry is highly regulated and subject to strict approvals and standards.
  • Limited Geographic Presence: Operations concentrated in selected Indian states may restrict nationwide growth.

Promoters

Amol Laxmikant Mujumdar

Swapan Premprakash Khandelwal

Registrar & documents

Lead manager

Cumulative Capital Private Limited

Registered office

103, F-1, Leela Apartment, Shilpa HSG Society, Near Saptagiri Nagar, Shanidham, Narendra Nagar, Nagpur, Maharashtra, 440015

+91 712 2786666

[email protected]Company website ↗

Frequently Asked Questions

What is Goldline Pharmaceutical IPO GMP today?

As of today, Goldline Pharmaceutical IPO Grey Market Premium (GMP) is reported at +₹12 per share. Based on the upper price band of ₹43, the estimated listing price is ₹55 (+27.9% expected listing gain). Please note that GMP is an unofficial market estimate for sentiment tracking and does not guarantee the actual listing price.

What is the lot size and minimum investment for Goldline Pharmaceutical IPO?

The minimum bid lot size for Goldline Pharmaceutical IPO is 3,000 shares. At the cut-off price of ₹43 per share, retail investors need a minimum application amount of ₹1,29,000 per lot. Retail applicants can apply for a maximum of 1 lots (up to ₹2,00,000).

When will Goldline Pharmaceutical IPO allotment status be announced?

The allotment status for Goldline Pharmaceutical IPO is scheduled to be finalized on 15 May 2026. If you applied for the IPO, you can verify whether shares have been allocated to your Demat account through Bigshare Services Private Limited's official portal or via BSE/NSE allotment portals.

How can I check Goldline Pharmaceutical IPO allotment status online by PAN?

To check Goldline Pharmaceutical IPO allotment status: 1) Visit the registrar portal (Bigshare Services Private Limited) or the BSE IPO allotment page. 2) Select 'Goldline Pharmaceutical Limited' from the company dropdown. 3) Choose 'PAN' as your identification mode and enter your 10-digit Permanent Account Number. 4) Click 'Search' to view your allotted share quantity and application status.

Explore More IPO Analysis & Live Tools

Compare the price band and required investment with company financials and official offer documents. Grey market premium (GMP) figures are indicative market estimates collected from primary market brokers and do not establish the official listing price.

Regulatory Disclaimer: Grey Market Premium (GMP) is an unofficial, unregulated indicator of market sentiment and does not represent a stock exchange transaction, guarantee, or investment advice. IPO Premiums is an informational and research portal and is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before applying for any IPO.